Mural Oncology plc
MURADelisted Dec 5, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001971543
Mural Oncology plc was delisted on Dec 5, 2025; its insiders filed their last Form 4 on Dec 5, 2025; 61 institutions reported holding it in 13F filings for Q3 2025, worth $11.0M in total; no superinvestor held it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Mural Oncology plc insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Mural Oncology plc, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Cuss Francis M | Director | – | Dec 5, 2025 | 1 |
| Jackson Scott Thomas | Director | – | Dec 5, 2025 | 1 |
| Golumbeski George | Director | – | Dec 5, 2025 | 1 |
| Keson-Brookes Maiken | Chief Legal Officer | 0 | Dec 5, 2025 | 1 |
| Cutler Adam D. | Chief Financial Officer | 0 | Dec 5, 2025 | 2 |
| Hickey Benjamin | Director | – | Dec 5, 2025 | 1 |
| Minegishi Sachiyo | Director | – | Dec 5, 2025 | 1 |
| Goodman Vicki L | Chief Medical Officer | 0 | Dec 5, 2025 | 2 |
| Loew Caroline | Chief Executive Officer | 0 | Dec 5, 2025 | 1 |
| ALTSCHULLER Susan | Director | 10,000 | Aug 15, 2024 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 8, 2024 (view filing) | Jul 8 | Same day | Loew CarolineChief Executive Officer | SSale | −12.5K | $2.91 | −$36.5K | −5.0%240.4K after | 10b5-1 |
| Jul 18, 2024 (view filing) | Jul 18 | Same day | Keson-Brookes MaikenSee Remarks | SSale | −2.16K | $3.41 | −$7.36K | −4.7%43.9K after | 10b5-1 |
| Aug 15, 2024 (view filing) | Aug 14 | 1 day | ALTSCHULLER SusanDirector | PPurchase | +10.0K | $3.21 | +$32.1K | New position10.0K after | |
| Nov 1, 2024 (view filing) | Oct 31 | 1 day | Cutler Adam D.Chief Financial Officer | SSale | −7.42K | $3.41 | −$25.3K | −9.4%71.4K after | 10b5-1 |
| Nov 8, 2024 (view filing) | Nov 7 | 1 day | Goodman Vicki LChief Medical Officer | SSale | −5.07K | $3.33 | −$16.9K | −6.9%67.9K after | 10b5-1 |
| Dec 18, 2024 (view filing) | Dec 17 | 1 day | Loew CarolineChief Executive Officer | SSale | −2.76K | $3.40 | −$9.39K | −1.1%237.6K after | 10b5-1 |
| Dec 26, 2024 (view filing) | Dec 23 | 3 days | Keson-Brookes MaikenSee Remarks | SSale | −2.56K | $3.27 | −$8.35K | −5.8%41.3K after | 10b5-1 |
| Feb 25, 2025 (view filing) | Feb 24 | 1 day | Goodman Vicki LChief Medical Officer | SSale | −13.2K | $3.89 | −$51.3K | −19.4%54.8K after | 10b5-1 |
| Mar 5, 2025 (view filing) | Mar 4 | 1 day | Loew CarolineChief Executive Officer | SSale | −4.31K | $3.36 | −$14.5K | −1.4%305.6K after | 10b5-1 |
| Mar 5, 2025 (view filing) | Mar 4-5 | 1 day | Keson-Brookes MaikenSee Remarks | SSale | −2.73K | $3.41 | −$9.31K | −3.6%73.6K after | 2 lots10b5-1 |
| Jul 9, 2025 (view filing) | Jul 7 | 2 days | Loew CarolineChief Executive Officer | SSale | −12.5K | $2.43 | −$30.5K | −4.1%293.1K after | 10b5-1 |
| Jul 22, 2025 (view filing) | Jul 18 | 4 days | Keson-Brookes MaikenSee Remarks | SSale | −2.16K | $2.48 | −$5.35K | −2.9%71.4K after | 10b5-1 |
| Jul 23, 2025 (view filing) | Jul 22 | 1 day | Keson-Brookes MaikenSee Remarks | SSale | −2.57K | $2.48 | −$6.38K | −3.6%68.8K after | 10b5-1 |
| Nov 10, 2025 (view filing) | Nov 10 | Same day | Goodman Vicki LChief Medical Officer | SSale | −5.04K | $2.08 | −$10.5K | −5.6%84.7K after | 10b5-1 |
| Nov 10, 2025 (view filing) | Nov 3 | 7 daysLate | Cutler Adam D.Chief Financial Officer | SSale | −7.15K | $2.09 | −$14.9K | −6.7%99.3K after | 10b5-1 |